The glofitamab-based regimen displayed manageable safety, with minimal high-grade CRS and infrequent low-grade ICANS, in relapsed/refractory LBCL.
Roman Fabbricatore
Advertisement
Articles by Roman Fabbricatore
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on AJMC
1
Trump Announces Deals With Lilly, Novo to Cut Weight Loss Drug Prices
2
CMS Announces GENEROUS Model to Lower Medicaid Drug Prices
3
Adolescents, Young Adults Use AI Chatbots for Mental Health Advice
4
FDA Approves Daratumumab and Hyaluronidase-fihj for High-Risk MM
5
